Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET

Company Participants

Hayleigh Collins - Director, Head of Corporate Communications and IR
Sean Nolan - CEO and Chairman
Sukumar Nagendran - President and Head of Research and Development
Kamran Alam - CFO

Conference Call Participants

Kristen Kluska - Cantor Fitzgerald
Elizabeth Webster - Goldman Sachs
Christopher Raymond - Piper Sandler
Gil Blum - Needham & Company
Joon So Lee - Truist Securities
Maurice Raycroft - Jefferies
Yanan Zhu - Wells Fargo Securities
Jack Allen - Robert W. Baird
Silvan Tuerkcan - JMP Securities

Operator

Greetings and welcome to the Taysha Gene Therapies Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Hayleigh Collins, Director and Head of Corporate Communications and Investor Relations. Thank you. You may begin.

Hayleigh Collins

Thank you. Good morning and welcome to Taysha's second quarter 2024 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the second quarter ended June 30, 2024. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's CEO; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer.

We will hold a question-and-answer session following our prepared remarks. Please note that on today's call, we will be making forward-looking statements including statements relating to the therapeutic and commercial potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in the patients dosed to date in clinical trial to positively impact the quality of life and also the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates including timelines for our clinical trials and reporting results therefrom, in our current cash resources supporting our planned operating expenses and capital requirements into the fourth quarter of 2026.

These statements may include but are not limited to the expected timing and results of clinical trials for our product candidates and other clinical and regulatory plans, and the market opportunity for those programs. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway and future operating results, discovery and development of product candidates, strategic alliances and intellectual property as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. These risks include uncertainties related to the timing and results of clinical trials of and regulatory interactions for our product candidates, our dependence upon strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirements of substantial funding to conduct our research and development activities. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the SEC, including our Annual Report on Form 10-K for the full year ended December 31st, 2023 and our quarterly report on Form 10-Q for the quarter ended June 30, 2024 that we filed today.